114 related articles for article (PubMed ID: 2208574)
1. Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells.
Limonta M; Biondi A; Giudici G; Specchia G; Catapano C; Masera G; Barbui T; D'Incalci M
Cancer Chemother Pharmacol; 1990; 26(5):340-2. PubMed ID: 2208574
[TBL] [Abstract][Full Text] [Related]
2. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.
Kuffel MJ; Reid JM; Ames MM
Cancer Chemother Pharmacol; 1992; 30(1):51-7. PubMed ID: 1586980
[TBL] [Abstract][Full Text] [Related]
3. Action mechanism of idarubicin (4-demethoxydaunorubicin) as compared with daunorubicin in leukemic cells.
Fukushima T; Ueda T; Uchida M; Nakamura T
Int J Hematol; 1993 Apr; 57(2):121-30. PubMed ID: 8494991
[TBL] [Abstract][Full Text] [Related]
4. A comparison of in vitro sensitivity of acute myeloid leukemia precursors to mitoxantrone, 4'deoxydoxorubicin, 4-demethoxydaunorubicin and daunorubicin.
Schölzel C; van Putten W; Löwenberg B
Leuk Res; 1986; 10(12):1455-9. PubMed ID: 3467144
[TBL] [Abstract][Full Text] [Related]
5. Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia.
Yang GS; Minden MD; McCulloch EA
Leukemia; 1994 Dec; 8(12):2065-75. PubMed ID: 7807996
[TBL] [Abstract][Full Text] [Related]
6. Induction of DNA damage, inhibition of DNA synthesis and suppression of c-myc expression by the anthracycline analog, idarubicin (4-demethoxy-daunorubicin) in the MCF-7 breast tumor cell line.
Gewirtz DA; Randolph JK; Chawla J; Orr MS; Fornari FA
Cancer Chemother Pharmacol; 1998; 41(5):361-9. PubMed ID: 9523731
[TBL] [Abstract][Full Text] [Related]
7. Enhanced sensitivity of the rat hepatoma cell to the daunorubicin analogue 4-demethoxydaunorubicin associated with induction of DNA damage.
Woods KE; Ellis AL; Randolph JK; Gewirtz DA
Cancer Res; 1989 Sep; 49(17):4846-51. PubMed ID: 2758416
[TBL] [Abstract][Full Text] [Related]
8. Influence of idarubicinol on the antileukemic effect of idarubicin.
Fukushima T; Kawai Y; Urasaki Y; Yoshida A; Ueda T; Nakamura T
Leuk Res; 1994 Dec; 18(12):943-7. PubMed ID: 7996875
[TBL] [Abstract][Full Text] [Related]
9. Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study.
Pannuti F; Camaggi CM; Strocchi E; Comparsi R; Angelelli B; Pacciarini MA
Cancer Chemother Pharmacol; 1986; 16(3):295-9. PubMed ID: 3457647
[TBL] [Abstract][Full Text] [Related]
10. Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia.
Daghestani AN; Arlin ZA; Leyland-Jones B; Gee TS; Kempin SJ; Mertelsmann R; Budman D; Schulman P; Baratz R; Williams L
Cancer Res; 1985 Mar; 45(3):1408-12. PubMed ID: 3855696
[TBL] [Abstract][Full Text] [Related]
11. Daunorubicin-induced internucleosomal DNA fragmentation in acute myeloid cell lines.
Quillet-Mary A; Mansat V; Duchayne E; Come MG; Allouche M; Bailly JD; Bordier C; Laurent G
Leukemia; 1996 Mar; 10(3):417-25. PubMed ID: 8642856
[TBL] [Abstract][Full Text] [Related]
12. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells.
Berman E; McBride M
Blood; 1992 Jun; 79(12):3267-73. PubMed ID: 1596567
[TBL] [Abstract][Full Text] [Related]
13. Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state.
Minderman H; Linssen P; van der Lely N; Wessels J; Boezeman J; de Witte T; Haanen C
Leukemia; 1994 Mar; 8(3):382-7. PubMed ID: 8127143
[TBL] [Abstract][Full Text] [Related]
14. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
[TBL] [Abstract][Full Text] [Related]
15. Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin.
Fukushima T; Inoue H; Takemura H; Kishi S; Yamauchi T; Inai K; Nakayama T; Imamura S; Urasaki Y; Nakamura T; Ueda T
Leuk Res; 1998 Jul; 22(7):625-9. PubMed ID: 9680113
[TBL] [Abstract][Full Text] [Related]
16. DNA damage by anthracycline drugs in human leukemia cells.
Schwartz HS; Kanter PM
Cancer Lett; 1981 Sep; 13(4):309-13. PubMed ID: 6946856
[TBL] [Abstract][Full Text] [Related]
17. Formation, resealing and persistence of DNA breaks produced by 4-demethoxydaunorubicin in P388 leukemia cells.
Capranico G; Tinelli S; Zunino F
Chem Biol Interact; 1989; 72(1-2):113-23. PubMed ID: 2555070
[TBL] [Abstract][Full Text] [Related]
18. Effect of daunorubicin, carminomycin, idarubicin and 4-demethoxydaunorubicinol against human normal myeloid stem cells and human malignant cells in vitro.
Dodion P; Sanders C; Rombaut W; Mattelaer MA; Rozencweig M; Stryckmans P; Kenis Y
Eur J Cancer Clin Oncol; 1987 Dec; 23(12):1909-14. PubMed ID: 3481336
[TBL] [Abstract][Full Text] [Related]
19. Effects of an IL-1 receptor antagonist on acute myeloid leukemia cells.
Yin M; Gopal V; Banavali S; Gartside P; Preisler H
Leukemia; 1992 Sep; 6(9):898-901. PubMed ID: 1387693
[TBL] [Abstract][Full Text] [Related]
20. Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response.
Colado E; Paíno T; Maiso P; Ocio EM; Chen X; Alvarez-Fernández S; Gutiérrez NC; Martín-Sánchez J; Flores-Montero J; San Segundo L; Garayoa M; Fernández-Lázaro D; Vidriales MB; Galmarini CM; Avilés P; Cuevas C; Pandiella A; San-Miguel JF
Haematologica; 2011 May; 96(5):687-95. PubMed ID: 21330323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
